One of the antibodies used to target EGFR had been the following: Erbitux (cetuximab) with antiproliferative activity and the ability to block the cell cycle in G1 phase; until now Erbitux has been used in the therapy of colorectal cancer (CRC) and clinical trials are in progress for pancreatic cancer, head and neck squamous cell carcinoma, or NSCLC [8, 57]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.